

DATASHEET

GSK J4

Product overview

Name	GSK J4
Cat No	HB1407
Alternative names	GSK-J4; GSKJ4
Biological action	Inhibitor
Purity	>99%
Description	JMJD3 / UTX Histone demethylase inhibitor

Biological Data

Biological description	JMJD3 and UTX histone demethylase inhibitor, GSK J1 prodrug. Cell permeable. Reduces macrophage proinflammatory cytokine production. Improves survival in Cardio-facio-cutaneous (CFC) syndrome in mice and inhibits growth of T-cell acute lymphoblastic leukaemia cancer cells.
-------------------------------	---


Solubility & Handling

Storage instructions	Room temperature
Solubility overview	Soluble in DMSO (100mM) or ethanol (100mM)
Important	This product is for RESEARCH USE ONLY and is not intended for therapeutic or diagnostic use. Not for human or veterinary use.

Chemical Data

Chemical name N-[2-(2-Pyridinyl)-6-(1,2,4,5-tetrahydro-3H-3-benzazepin-3-yl)-4-pyrimidinyl]-β-alanine ethyl ester
Molecular Weight 417.5

Chemical structure



Molecular Formula C₂₄H₂₇N₅O₂
CAS Number 1373423-53-0
PubChem identifier 71729975
SMILES O=C(CCNC1=NC(C2=CC=CC=N2)=NC(N3CCC(C=CC=C4)=C4CC3)=C1)OCC
InChiKey WBKCKEHGXNWYMO-UHFFFAOYSA-N

References

A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response.

Kruidenier L *et al* (2012) Nature 488(7411)

PubMedID [22842901](#)

New BRAF knockin mice provide a pathogenetic mechanism of developmental defects and a therapeutic approach in cardio-facio-cutaneous syndrome.

Inoue S *et al* (2014) Hum Mol Genet 23(24)

PubMedID [25035421](#)

Contrasting roles of histone 3 lysine 27 demethylases in acute lymphoblastic leukaemia.

Ntziachristos P *et al* (2014) Nature 514(7523)

PubMedID [25132549](#)
